
Teneligliptin (20mg) + Metformin (500mg)
Active composition
+1 more active ingredient
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Glycoten-M 500 Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby lowering both fasting and postprandial blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic regulation. The extended-release formulation of Glycoten-M 500 facilitates once-daily dosing, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is indicated as adjunctive therapy to diet and exercise for adult patients inadequately controlled on monotherapy or lifestyle modifications alone. Glycoten-M 500 should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended to optimize therapeutic outcomes. This product should be prescribed and used under medical supervision to ensure safety and efficacy in managing type 2 diabetes mellitus.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Glycoten-M 500 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Glycoten-M 500 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Glycoten-M 500 Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Glycoten-M 500 Tablet ER may be needed. Please consult your doctor. Use of Glycoten-M 500 Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Glycoten-M 500 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Glycoten-M 500 Tablet ER is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Glycoten-M 500 Tablet ER

Metformin (500mg) + Teneligliptin (20mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Glycoten-M 500 Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to improve glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby lowering both fasting and postprandial blood glucose levels. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic regulation. The extended-release formulation of Glycoten-M 500 facilitates once-daily dosing, promoting better patient adherence and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is indicated as adjunctive therapy to diet and exercise for adult patients inadequately controlled on monotherapy or lifestyle modifications alone. Glycoten-M 500 should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended to optimize therapeutic outcomes. This product should be prescribed and used under medical supervision to ensure safety and efficacy in managing type 2 diabetes mellitus.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Glycoten-M 500 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Glycoten-M 500 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Glycoten-M 500 Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Glycoten-M 500 Tablet ER may be needed. Please consult your doctor. Use of Glycoten-M 500 Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Glycoten-M 500 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Glycoten-M 500 Tablet ER is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Glycoten-M 500 Tablet ER













